161 related articles for article (PubMed ID: 19201468)
21. Extramedullary Multiple Myeloma: A Patient-Focused Review of the Pathogenesis of Bone Marrow Escape.
Gupta S; Master S; Graham C
World J Oncol; 2022 Oct; 13(5):311-319. PubMed ID: 36406195
[TBL] [Abstract][Full Text] [Related]
22. Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma.
Chang H; Yeung J; Qi C; Xu W
Br J Haematol; 2007 Aug; 138(3):324-9. PubMed ID: 17555471
[TBL] [Abstract][Full Text] [Related]
23. [Expression of CD56 in Multiple Myeloma Cells and Its Relationship with Extramedullary Disease and Extramedullary Relapse].
Li G; Huang XJ; Niu T; Wei C; Cheng MX; Han CJ; Sun YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):553-556. PubMed ID: 33812430
[TBL] [Abstract][Full Text] [Related]
24. [The expression of p53 protein in patients with multiple myeloma].
Marković O; Marisavljević D; Cemerikić V; Perunicić M; Colović M
Srp Arh Celok Lek; 2007; 135(1-2):43-7. PubMed ID: 17503567
[TBL] [Abstract][Full Text] [Related]
25. Cytodiagnosis of extramedullary plasmacytomas.
Goel G; Rai S; Naik R; Gupta A; Baliga P; Sinha R
Acta Cytol; 2010; 54(3):255-8. PubMed ID: 20518407
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical expression of the p53, p21/Waf-1, Rb, p16 and Ki67 proteins in multiple myeloma.
Kanavaros P; Stefanaki K; Vlachonikolis J; Papalazarou D; Rontogianni D; Arvanitis D; Antonakopoulos G; Gorgoulis V; Bai M; Agnantis NJ
Anticancer Res; 2000; 20(6B):4619-25. PubMed ID: 11205312
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical analysis of cyclin D1 and p53 in multiple myeloma: relationship to proliferative activity and prognostic significance.
Markovic O; Marisavljevic D; Cemerikic V; Suvajdzic N; Milic N; Colovic M
Med Oncol; 2004; 21(1):73-80. PubMed ID: 15034217
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological features of extramedullary recurrence/relapse of multiple myeloma.
Cerny J; Fadare O; Hutchinson L; Wang SA
Eur J Haematol; 2008 Jul; 81(1):65-9. PubMed ID: 18462256
[TBL] [Abstract][Full Text] [Related]
29. p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.
Chen MH; Qi CX; Saha MN; Chang H
Am J Clin Pathol; 2012 Feb; 137(2):208-12. PubMed ID: 22261445
[TBL] [Abstract][Full Text] [Related]
30. Clinical analysis of 40 multiple myeloma patients with extramedullary plasmacytoma of the head.
Sun WJ; Zhang JJ; An N; Shen M; Huang ZX; Li X
J Int Med Res; 2016 Dec; 44(6):1462-1473. PubMed ID: 28322099
[TBL] [Abstract][Full Text] [Related]
31. Hierarchy of mono- and biallelic
Munawar U; Rasche L; Müller N; Vogt C; Da-Via M; Haertle L; Arampatzi P; Dietrich S; Roth M; Garitano-Trojaola A; Steinhardt MJ; Strifler S; Gallardo M; Martinez-Lopez J; Bargou RC; Heckel T; Einsele H; Stühmer T; Kortüm KM; Barrio S
Blood; 2019 Sep; 134(10):836-840. PubMed ID: 31340981
[No Abstract] [Full Text] [Related]
32. Expression of CD19 and lack of miR-223 distinguish extramedullary plasmacytoma from multiple myeloma.
Yu SC; Chen SU; Lu W; Liu TY; Lin CW
Histopathology; 2011 May; 58(6):896-905. PubMed ID: 21401705
[TBL] [Abstract][Full Text] [Related]
33. p53 gene mutations are rare in patients but common in patient-originating cell lines in multiple myeloma.
Ollikainen H; Syrjänen S; Koskela K; Pelliniemi TT; Pulkki K
Scand J Clin Lab Invest; 1997 Jul; 57(4):281-9. PubMed ID: 9249875
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Whole-Body DWI and
Chen J; Li C; Tian Y; Xiao Q; Deng M; Hu H; Wen B; He Y
AJR Am J Roentgenol; 2019 Sep; 213(3):514-523. PubMed ID: 31166755
[No Abstract] [Full Text] [Related]
35. Clinical course of solitary extramedullary plasmacytoma.
Liebross RH; Ha CS; Cox JD; Weber D; Delasalle K; Alexanian R
Radiother Oncol; 1999 Sep; 52(3):245-9. PubMed ID: 10580871
[TBL] [Abstract][Full Text] [Related]
36. Long non-coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma.
Handa H; Kuroda Y; Kimura K; Masuda Y; Hattori H; Alkebsi L; Matsumoto M; Kasamatsu T; Kobayashi N; Tahara KI; Takizawa M; Koiso H; Ishizaki T; Shimizu H; Yokohama A; Tsukamoto N; Saito T; Murakami H
Br J Haematol; 2017 Nov; 179(3):449-460. PubMed ID: 28770558
[TBL] [Abstract][Full Text] [Related]
37. CD56 expression in human myeloma cells derived from the neurogenic gene expression: possible role of the SRY-HMG box gene, SOX4.
Iqbal MS; Otsuyama K; Shamsasenjan K; Asaoku H; Kawano MM
Int J Hematol; 2010 Mar; 91(2):267-75. PubMed ID: 20049565
[TBL] [Abstract][Full Text] [Related]
38. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
39. A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells.
Leotta M; Biamonte L; Raimondi L; Ronchetti D; Di Martino MT; Botta C; Leone E; Pitari MR; Neri A; Giordano A; Tagliaferri P; Tassone P; Amodio N
J Cell Physiol; 2014 Dec; 229(12):2106-16. PubMed ID: 24819167
[TBL] [Abstract][Full Text] [Related]
40. Atypical progression of multiple myeloma with extensive extramedullary disease.
Jowitt SN; Jacobs A; Batman PA; Sapherson DA
J Clin Pathol; 1994 Mar; 47(3):269-71. PubMed ID: 8163701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
